Canaccord reiterates a Buy rating on PacBio (PACB) with a $3 price target following the company’s Q4 report. The firm says that although PacBio forecasts modest sales growth in 2025, it remains optimistic the company should be able to return to growth over time due to new products and improved execution. Canaccord points out management incorporated National Institutes of Health-related uncertainty into its 2025 guidance. The firm is optimistic PacBio’s is positioned “relatively well” in the current environment and believes the shares do not reflect the company’s growth potential. The stock in morning trading is up 24% to $1.84.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- PacBio price target lowered to $3.50 from $4 at TD Cowen
- Pacific Biosciences: Strategic Growth Amidst Funding Challenges Supports Buy Rating
- PacBio Navigates Financial Challenges with Strategic Advances
- Pacific Biosciences: Buy Rating Amidst Conservative Guidance and Strategic Growth Initiatives
- PacBio reports Q4 EPS (20c), consensus (17c)